research use only
Cat.No.S5001
| Related Targets | EGFR STAT Pim |
|---|---|
| Other JAK Inhibitors | BMS-986165 (Deucravacitinib) AZD1480 WP1066 Momelotinib (CYT387) Filgotinib (GLPG0634) AT9283 Gandotinib (LY2784544) Pacritinib (SB1518) NVP-BSK805 2HCl TG101209 |
|
In vitro |
DMSO
: 100 mg/mL
(198.21 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about CP-690550 (Tofacitinib) Citrate solubility in DMSO or water
Read more about CP-690550 (Tofacitinib) Citrate working concentrations for cell culture treatment
| Information | CP-690550 (Tofacitinib) Citrate is a potent JAK1 inhibitor. It affects JAK/STAT and IL-17A signaling by inhibiting JAK1 activation, effectively preventing high glucose- and IL-17A-mediated tight junction disruption and protecting blood-retinal barrier integrity. |
|---|---|
| Primary Applications and Mechanism of Action |
Read more about CP-690550 (Tofacitinib) Citrate Mechanism of Action
| Molecular Weight | 504.49 | Formula | C16H20N6O.C6H8O7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 540737-29-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Tasocitinib Citrate,CP-690550 | Smiles | CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
What is the difference between the two products (S5001, S2789)?
Answer:
Tofacitinib (S2789) is the base form of this compound. The biological activity of these two compounds is the same. However, S5001 is better than S2789 for oral gavage.